Showing 3061-3070 of 3315 results for "".
- Alcon to Hold Second Annual Alcon Retina Fellows Institutehttps://modernod.com/news/alcon-to-hold-second-annual-alcon-retina-fellows-institute/2477120/Alcon announced it will host future ophthalmology leaders for the second annual Alcon Retina Fellows Institute, an educational experience where first year retina fellows gain hands-on surgical training and mentorship from some of the leading ophthalmologists in the field, according to a company n
- CooperVision Earns Global Impact Award for Rebate Donation Program Resulting in $800,000 Raised for Optometry Giving Sighthttps://modernod.com/news/coopervision-earns-global-impact-award-for-rebate-donation-program-resulting-in-800000-raised-for-optometry-giving-sight/2477119/CooperVision offers a contact lens rebate donation program that enables consumers to designate all or part of their rebates to be given to Optometry Giving Sight (OGS). Seven years after the launch of that program, CooperVision has been recognized by 360insights, the company’s rebate and incentiv
- EnChroma Makes New Indoor Color Blind Glasses Available to the Publichttps://modernod.com/news/enchroma-makes-new-indoor-color-blind-glasses-available-to-the-public/2477109/EnChroma announced the launch of EnChroma Cx1 Indoor DT, an improved indoor lens designed specifically for Deutan-type color blindness. The glasses are now available for purchase online at
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UKhttps://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-uk/2477102/Johnson & Johnson Vision announced the national availability of Acuvue Oasys with Transitions Light Intelligent Technology in the UK. The first-of-its-kind photochromic contact lens offers superior visual performance indoor and outdoor, day and night, according to a company news release.
- Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernod.com/news/baring-private-equity-asia-agrees-to-acquire-lumenis/2477103/Baring Private Equity Asia announced that its affiliated private equity funds have agreed to acquire Lumenis, a leading provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an ent
- Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Programhttps://modernod.com/news/aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-to-advance-its-dry-eye-program/2477097/Aerie Pharmaceuticals announced it is acquiring Avizorex Pharma, a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. AVX completed a phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The acti
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea
- Bausch + Lomb and TerraCycle Announce Donation of New Custom Training Modules to Guide Dog Foundationhttps://modernod.com/news/bausch-lomb-and-terracycle-announce-donation-of-new-custom-training-modules-to-guide-dog-foundation/2477087/Bausch + Lomb in collaboration with TerraCycle, a leader in the collection and repurposing of hard-to-recycle post-consumer waste, announced the donation of custom training modules to the Guide Dog Foundation, a national not-for-profit that trains guide dogs for people who are blind or visually i
- Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol Eye Dropshttps://modernod.com/news/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops/2477075/Ocuphire Pharma announced statistically significant and clinically meaningful results from its recently completed two phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Topline results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmatory
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m